EPCORE DLBCL-2: Epcoritamab Plus R-CHOP Cuts Risk 51%
Epcoritamab plus R-CHOP met the primary PFS endpoint in the Phase 3 EPCORE DLBCL-2 trial, cutting progression risk 51%. What it means for DLBCL.
FDA Extends Review of Novo Denecimig Over Facility Issues
FDA extended its denecimig review as manufacturing-site remediation continues. No efficacy or safety issues were cited; Novo now expects a US launch in H1 2027.